There is one clinical trial.
TACE against HCC is the standard of care for BCLC stage B patients. In this exploratory study, the investigators assess the efficacy of TACE with or without adagloxad simolenin/OBI-821 treatment in GALNT14 "non-TT" HCC population.
5. Child-Pugh functional class A or B. 6. GALNT14- rs9679162 "non TT" genotype 7.
Description: time-to-intrahepatic total tumor volume progressionMeasure: time-to-ITTVP Time: From enrollment till 36 months of follow-up.